ProCE Banner Activity

ROAR: Phase II Study of Dabrafenib + Trametinib for Relapsed/Refractory BRAF V600E–Mutated Hairy Cell Leukemia

Slideset Download
Conference Coverage
Combined BRAF and MEK inhibition was well tolerated and achieved a high rate of durable responses in this heavily pretreated patient population.

Released: December 10, 2018

Expiration: December 09, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology